Dopamine D2 receptor upregulation in rat neostriatum following in vivo infusion of forskolin

NeuroReport

Volumn 8, Issue 13, 1997, Pages 2971-2976

  Wanderoy, Maria H ^a,b   Westlind Danielsson, Anita ^a   Ahlenius, Sven ^a  

^a Astra Arcus AB   (Sweden)

^b STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

7 OH DPAT; cAMP; DOPA; Dopamine D1 receptor; Dopamine D2 receptor; Downregulation; Forskolin; Neostriatum; Upregulation

Indexed keywords

2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 3 HYDROXYBENZYLHYDRAZINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; CARBOXYLYASE; DOPA; DOPAMINE; DOPAMINE 2 RECEPTOR; FLUPENTIXOL; FORSKOLIN; RACLOPRIDE; RACLOPRIDE TARTRATE; 7 HYDROXY 2 N,N DIPROPYLAMINOTETRALIN; 7-HYDROXY-2-N,N-DIPROPYLAMINOTETRALIN; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; SALICYLAMIDE DERIVATIVE; TETRALIN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DOPAMINE METABOLISM; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; NEOSTRIATUM; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RAT; RECEPTOR DENSITY; RECEPTOR UPREGULATION; SECOND MESSENGER; SUBCUTANEOUS DRUG ADMINISTRATION; ANIMAL; BRAIN VENTRICLE; DOSE RESPONSE; DRUG EFFECT; IN VITRO STUDY; INFUSION; METABOLISM; UPREGULATION; WISTAR RAT;

ANIMALS; CEREBRAL VENTRICLES; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FORSKOLIN; INFUSIONS, PARENTERAL; MALE; NEOSTRIATUM; RACLOPRIDE; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2; SALICYLAMIDES; TETRAHYDRONAPHTHALENES; UP-REGULATION;

EID: 0031559640     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-199709080-00033     Document Type: Article

References (25)

1. Johansson MH and Westlind-Danielsson A. Eur J Pharmacol 269, 149-155 (1994).
2. Wanderoy MH and Westlind-Danielsson A. Cell Mol Neurobiol In press.
3. Baker GB and Greenshaw AJ. Cell Mol Neurobiol 9, 1-44 (1989).
4. Kane JM. Tardive dyskinesia: epidemiological and clinical presentation. In: Bloom FE and Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press, 1995: 1485-1495.
5. Ahlenius S, Ericson E, Högberg K and Wijkström A. Pharmacol Toxicol 68, 302-309 (1991).
6. Andén N-E. Regulation of monoamine synthesis and utilization by receptors. In: Szekeres L, ed. Adrenergic Activators and Inhibitors. Handbook of Experimental Pharmacology, Vol. 54/I. Berlin: 1980: 429-462.
7. Carlsson A, Davis JN, Kehr W et al. Naunyn-Schmiedeberg's Arch Pharmacol 275, 153-168 (1972).
8. Paxinos G and Watson C. The Rat Brain in Stereotaxic Coordinates, 2nd edn. London: Academic Press, 1986.
9. Malmberg Å and Mohell N. J Pharmacol Exp Ther 274, 790-797 (1995).
10. Jackson DM, Mohell N, Georgieva J et al. Naunyn-Schmiedeberg's Arch Pharmacol 351, 146-155 (1995).
11. Ericson E, Samuelsson J and Ahlenius S. Pharmacol Toxicol Meth 25, 111-122 (1991).
12. Magnusson O, Nilsson LB and Westerlund D. J Chromatogr 221, 237-247 (1980).
13. Munson PJ and Rodbard D. Anal Biochem 107, 220-239 (1980).
14. Winer BJ. Statistical Principles in Experimental Design. New York: McGraw-Hill, 1971.
15. Owen F, Cross AJ, Waddington JL et al. Life Sci 26, 55-59 (1980).
16. Westlind-Danielsson A, Ericsson G and Wanderoy MH. Soc Neurosci Abstr 20, 522 (1994).
17. Jackson DM and Westlind-Danielsson A. Pharmacol Ther 64, 291-369 (1994).
18. Harada K, Meller E and Goldstein M. Eur J Pharmacol 188, 123-128 (1990).
19. Ahlenius S. Naunyn-Schmiedeberg's Arch Pharmacol 345, 516-522.
20. Kebabian JW and Calne DB. Nature 277, 93-96.
21. Barton AC and Sibley DR. Mol Pharmacol 38, 531-541 (1990).
22. Bates MD, Olsen CL, Becker BN et al. J Biol Chem 268, 14757-14763 (1993).
23. Ng GYK, Trogadis J, Stevens J et al. Proc Natl Acad Sci USA 92, 10157-10161 (1995).
24. Suzdak PD and Browne RG. Psychopharmacology 87, 464-467 (1985).
25. Simpson JN and McGinty JF. NeuroReport 5, 1213-1216 (1994).